Eli Lilly selected Huntsville, Alabama as the site for a $6 billion active pharmaceutical ingredient (API) facility that will produce peptide and small‑molecule APIs including its oral GLP‑1 candidate orforglipron. The company said construction will start in 2026 with completion targeted for 2032 and expects to hire about 450 permanent staff plus roughly 3,000 construction workers. Lilly cited proximity to the HudsonAlpha Institute for Biotechnology and regional manufacturing expertise in its site choice. Lilly frames the investment as part of a broader $27 billion U.S. manufacturing expansion to onshore API production and boost supply‑chain resilience. The Huntsville plant is the third of four mega‑sites Lilly has announced; the company said it will disclose the fourth location soon. The move signals continued industrialization of GLP‑1 manufacturing capacity as competitors (notably Novo Nordisk) scale to meet global demand. Local and state officials welcomed the project for its job and economic impact; Lilly emphasized the site’s role in producing ingredients for both obesity and other therapeutic programs. The timeline—multi‑year build and commissioning—means supply contributions for orforglipron are medium‑term, while regulatory filings for the drug are expected by year‑end from Lilly.